News Releases

Mavorixafor selected for LLS’s Therapy Acceleration Program ® (TAP) CAMBRIDGE, Mass. & RYE BROOK, N.Y. --(BUSINESS WIRE)--May 15, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq:XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 24, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of E....

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 12, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today the pricing of its previously announced und...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 11, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today that it has commenced an underwritten publi...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of Murray Stewart , M.D., as...

Expects to commence the global Phase 3 pivotal trial of mavorixafor for the treatment of patients with Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome in second quarter 2019 having finalized the protocol based on FDA guidance Receives World Health Organ...

– Newly Nasdaq-listed XFOR focused on the development of novel therapeutics for the treatment of rare diseases – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 13, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR, as of March 14, 2019 ), a clinical-stage biopharmaceutical company focused ...

X4 is advancing clinical and commercial plans for X4P-001 in a rare genetic, primary immunodeficiency disease that currently has no approved treatments   Additional Phase 2 results presented at the 60 th  Annual Meeting of the American Society of Hematology CAMBRIDGE, MA – Decemb...

Merger Expected to Create NASDAQ-listed, Late-stage Biopharmaceutical Company Focused on Rare Diseases and Cancer Phase 3 Clinical Trial for X4P-001, a Novel CXCR4 Antagonist, Anticipated to Start 1H 2019 Conference call to be held today at 8:30 AM ET CAMBRIDGE, Mass., WALTHAM, M...

Clinical data demonstrate single agent X4P-001-IO modulated the immune cell profile in the tumor microenvironment  and increased CD8+ T cell infiltration Data presented at the Society for Immunotherapy of Cancer’s (SITC) 33 rd  Annual Meeting CAMBRIDGE, Mass., November 6, 2018  –...

Leader brings expertise in financing, corporate planning and R&D strategy for biotechnology companies   Cambridge, MA – November 5, 2018  –  X4 Pharmaceuticals , a clinical stage biotechnology company developing novel oral CXCR4 antagonists to improve immune cell trafficking ...

Study designed to evaluate X4P-001-RD in a rare genetic, primary immunodeficiency disease to be presented at the American Society of Hematology meeting CAMBRIDGE, MA, November 1, 2018  –  X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonist...

Findings with combination therapy of anti-PD-1 and CXCR4 antagonist in patients with clear cell renal cell carcinoma (ccRCC) presented  in Poster Discussion session at ESMO 2018   Cambridge, MA – October 19, 2018  –  X4 Pharmaceuticals , a clinical stage biotechnology company dev...

CAMBRIDGE, Mass. October 15, 2018  –  X4 Pharmaceuticals , a clinical stage biotechnology company developing novel  CXCR4  antagonist drugs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the Company’s drug candidate, X4P-...

Three poster presentations showcased at NORD Rare Disease Summit Company continues to support genetic screening program to aid in diagnosis of patients with WHIM syndrome CAMBRIDGE, Mass. October 15, 2018  –  X4 Pharmaceuticals , a clinical stage biotechnology company developing ...

Data to highlight X4P-001-IO, orally bioavailable CXCR4 antagonist, in advanced renal cell carcinoma and melanoma CAMBRIDGE, Mass., October 9, 2018  –  X4 Pharmaceuticals , a clinical-stage biotechnology company developing novel  CXCR4  allosteric antagonist drug candidates desig...

Mr. Mostafa brings expertise in biotechnology financing and transactional experience to strengthen management team for next stage of company growth CAMBRIDGE, Mass., September 27, 2018  –  X4 Pharmaceuticals , a clinical-stage biotechnology company developing novel  CXCR4  allost...

Mr. Wyzga brings leadership experience, including in rare diseases and cancer CAMBRIDGE, MA – July  12,  2018  –  X4 Pharmaceuticals , a clinical-stage biotechnology company developing novel  CXCR4  allosteric antagonist drug candidates designed to improve immune cell trafficking...

Dose dependent increases in absolute neutrophil and lymphocyte counts observed in all patients treated with X4P-001-RD X4P-001-RD was well tolerated and a recommended dose of future Phase 3 study has been established Interim report from the Phase 2 study presented at the 23 rd  E...

Favorable response rates and combinability demonstrated in heavily pretreated patients Results presented at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting CAMBRIDGE, Mass., June 2, 2018 –  X4 Pharmaceuticals, a clinical stage biotechnology company developin...